HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research report released on Friday, Benzinga reports. The firm currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.53) EPS and FY2027 earnings at $1.29 EPS.
Separately, StockNews.com cut shares of Galectin Therapeutics from a hold rating to a sell rating in a research report on Thursday, July 18th.
Get Our Latest Analysis on Galectin Therapeutics
Galectin Therapeutics Trading Up 1.3 %
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). As a group, sell-side analysts predict that Galectin Therapeutics will post -0.66 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $43,000. Rhumbline Advisers acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter worth about $44,000. Retirement Guys Formula LLC boosted its holdings in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after buying an additional 12,232 shares during the period. Solutions 4 Wealth Ltd acquired a new position in Galectin Therapeutics in the 4th quarter valued at about $60,000. Finally, Traynor Capital Management Inc. raised its holdings in Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after acquiring an additional 8,164 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
See Also
- Five stocks we like better than Galectin Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Buy P&G Now, Before It Sets A New All-Time High
- 2 Option Strategies to Maximize Profits in a Bear Market
- 5 discounted opportunities for dividend growth investors
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.